Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-18
2005-10-18
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S231200, C514S406000, C544S106000, C544S111000, C544S140000, C544S358000, C544S371000, C546S184000, C546S192000, C546S199000, C548S356100, C548S361100, C548S362500
Reexamination Certificate
active
06956036
ABSTRACT:
Substituted 1-(α-alkyl-ethylamino)-1H-indazol-6-ols useful for lowering and controlling IOP and treating glaucoma are disclosed
REFERENCES:
patent: 3994890 (1976-11-01), Fujimura et al.
patent: 4585869 (1986-04-01), Ibuki et al.
patent: 4690931 (1987-09-01), Wick et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5494928 (1996-02-01), Bös
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6552062 (2003-04-01), Adams et al.
patent: 0 985 414 (2000-03-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 98/30548 (1998-07-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 99/59499 (1999-11-01), None
patent: WO 99/59499 (1999-11-01), None
patent: WO 00/12481 (2000-03-01), None
patent: WO 00/12481 (2000-03-01), None
patent: WO 00/16761 (2000-03-01), None
patent: WO 00/16761 (2000-03-01), None
patent: WO 00/17170 (2000-03-01), None
patent: WO 00/17170 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
Bodar, Nicholas, et al., “Improved Delivery Through Biological Membranes, XVII3. A Site-Specific Chemical Delivery System as a Short-Acting Mydriatic Agent”, Pharm. Res., 168-173 (1984).
Bowen et al., “Nonlinear regression using spreadsheets”, Trends in Pharmacological Sciences, 16:413-417 (1995).
Florella, et al., “Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives”, Psychopharmacology, 121:357-363 (1995).
Gever, Gabriel, “Hydrazinoalkanols”, J. Amer. Chem. Soc., 76:1283-1285 (1954).
Griffin, B.W., et al., “Pharmacological Characterization of an FP Prostaglandin Receptor on Rat Vascular Smooth Muscle Cells (A7r5) Coupled to Phosphoinositide Turnover and Intracellular Calcium Mobilization”, J. Pharmacol. Exp. Ther., 286:411-418 (1998).
Henke, B. R., et al., “Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists”, J. Med. Chem., 40:2706-2725 (1997).
Johnson, et al., “Binding To The Serotonin 5-HT2 Receptor By The Enantiomers of 1251-DOI”, Neuropharmacology, vol. 26, No. 12, 1803-0806 (1987).
Krapcho, A. P., et al., “Synthesis and Antitumor Evaluation of 2,5-Disubstituted-Indazolo[4,3-gh]isoquinolin-6(2H)-ones (9-Aza-anthrapyrazoles)”, J. Med. Chem., 41:5429-5444 (1998).
Krapcho, A. P., et al., “Synthesis of Hydroxy-substituted Aza-analogues of Antitumor Anthrapyrazoles”, J. Heterocycl. Chem., 35:895-906 (1998).
Sugrue, M.F., “New Approaches to Antiglaucoma Therapy”, Journal of Medicinal Chemistry, US, American Chemical Society, Washington, vol. 40, No. 18, pp 2793-2809 (Aug. 29, 1997) [D5].
Wrona, M. Z. and Dryhurst, Glenn, “Further Insights into the Oxidation Chemistry of 5-Hydroxytryptamine”, Journal of Pharmaceutical Sciences, 77:911-917 (1988).
Wrona, M. Z. and Dryhurst, G., “Oxidation Chemistry of 5-Hydroxytryptamine. 1, Mechanism and Products Formed at Micromoloar Concentrations” J. Org. Chem, 52:2817-2825 (1987).
Dantanarayana Anura P.
Feng Zixia
May Jesse A.
Alcon Inc.
Ryan Patrick M.
Schultz Teresa J.
Shameem Golam M M
LandOfFree
6-hydroxy-indazole derivatives for treating glaucoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-hydroxy-indazole derivatives for treating glaucoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-hydroxy-indazole derivatives for treating glaucoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3472972